Cantor Fitzgerald Forecasts NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Cantor Fitzgerald issued their FY2025 EPS estimates for Intellia Therapeutics in a research report issued on Monday, March 17th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will earn ($4.34) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Several other research firms also recently issued reports on NTLA. Wedbush restated a “neutral” rating and set a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. HC Wainwright began coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price objective on the stock. BMO Capital Markets dropped their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Finally, Truist Financial dropped their target price on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Stock Down 6.5 %

NTLA opened at $8.70 on Wednesday. Intellia Therapeutics has a 52-week low of $8.30 and a 52-week high of $28.54. The company has a market cap of $900.60 million, a P/E ratio of -1.60 and a beta of 1.97. The firm’s 50-day moving average price is $10.11 and its 200-day moving average price is $14.33.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 29,000 shares of company stock worth $352,551 in the last quarter. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its position in shares of Intellia Therapeutics by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after buying an additional 3,596 shares in the last quarter. Polar Asset Management Partners Inc. raised its stake in Intellia Therapeutics by 1,144.1% in the 4th quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company’s stock valued at $3,293,000 after purchasing an additional 259,700 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Intellia Therapeutics in the 4th quarter valued at $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Intellia Therapeutics by 5.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company’s stock valued at $5,634,000 after purchasing an additional 23,173 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its stake in Intellia Therapeutics by 226.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.